Back to top
more

Better trading starts here.

Company Summary

ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. They are one of the world's leading pure-play infusion therapy companies, with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps, dedicated and non-dedicated IV sets and needlefree connectors, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, they manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for hazardous IV drugs, and cardiac monitoring systems to optimize patient fluid levels.

General Information

ICU Medical, Inc

951 CALLE AMANECER

SAN CLEMENTE, CA 92763

Phone: 949-366-2183

Fax: 949-366-8368

Web: http://www.icumed.com

Email: ir@icumed.com

Industry Medical - Products
Sector Medical
Fiscal Year End December
Last Reported Quarter 6/30/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 8/5/2024

EPS Information

Current Quarter EPS Consensus Estimate 0.98
Current Year EPS Consensus Estimate 4.80
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 8/5/2024

Fundamental Ratios

P/E
P/E (F1) 26.25
Trailing 12 Months 21.07
PEG Ratio NA
EPS Growth
vs. Previous Year -58.62%
vs. Previous Quarter -51.61%
   
Sales Growth
vs. Previous Year -0.35%
vs. Previous Quarter -3.61%
   
Price Ratios
Price/Book 1.48
Price/Cash Flow 8.23
Price / Sales 1.36
ROE
6/30/24 NA
3/31/24 5.38
12/31/23 6.35
ROA
6/30/24 NA
3/31/24 2.58
12/31/23 3.03
Current Ratio
6/30/24 NA
3/31/24 2.61
12/31/23 2.53
Quick Ratio
6/30/24 NA
3/31/24 1.09
12/31/23 1.06
Operating Margin
6/30/24 NA
3/31/24 5.01
12/31/23 5.93
Net Margin
6/30/24 NA
3/31/24 -2.63
12/31/23 -1.31
Pre-Tax Margin
6/30/24 NA
3/31/24 -4.50
12/31/23 -3.47
Book Value
6/30/24 NA
3/31/24 84.87
12/31/23 87.96
Inventory Turnover
6/30/24 NA
3/31/24 2.08
12/31/23 2.03
Debt-to-Equity
6/30/24 NA
3/31/24 0.76
12/31/23 0.74
Debt to Capital
6/30/24 NA
3/31/24 43.10
12/31/23 42.63